Business Description
Sarepta Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US8036071004
Description
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.86 | |||||
Equity-to-Asset | 0.34 | |||||
Debt-to-Equity | 1.15 | |||||
Debt-to-EBITDA | 7.47 | |||||
Interest Coverage | 4.23 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 2.48 | |||||
Beneish M-Score | -1.2 | |||||
WACC vs ROIC |
Growth Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 24.8 | |||||
3-Year EBITDA Growth Rate | 6.4 | |||||
3-Year EPS without NRI Growth Rate | 30.8 | |||||
3-Year Book Growth Rate | -1.5 | |||||
Future 3-5Y Total Revenue Growth Rate | 46.29 |
Momentum Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 45.78 | |||||
9-Day RSI | 46.19 | |||||
14-Day RSI | 47.67 | |||||
6-1 Month Momentum % | -18.23 | |||||
12-1 Month Momentum % | 36.52 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.84 | |||||
Quick Ratio | 3.03 | |||||
Cash Ratio | 1.71 | |||||
Days Inventory | 629.62 | |||||
Days Sales Outstanding | 84.22 | |||||
Days Payable | 180.34 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -5.7 | |||||
Shareholder Yield % | 0.21 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 85.92 | |||||
Operating Margin % | 4.94 | |||||
Net Margin % | 7.43 | |||||
FCF Margin % | -29.29 | |||||
ROE % | 12.48 | |||||
ROA % | 3.66 | |||||
ROIC % | 4.93 | |||||
ROC (Joel Greenblatt) % | 16.84 | |||||
ROCE % | 5.49 |
GF Value Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 78.9 | |||||
Forward PE Ratio | 10.66 | |||||
PE Ratio without NRI | 74.49 | |||||
PEG Ratio | 24.03 | |||||
PS Ratio | 7.45 | |||||
PB Ratio | 9.5 | |||||
Price-to-Tangible-Book | 9.72 | |||||
EV-to-EBIT | 79.47 | |||||
EV-to-Forward-EBIT | 7.21 | |||||
EV-to-EBITDA | 63.06 | |||||
EV-to-Forward-EBITDA | 7 | |||||
EV-to-Revenue | 7.2 | |||||
EV-to-Forward-Revenue | 3.73 | |||||
EV-to-FCF | -24.57 | |||||
Price-to-DCF (Earnings Based) | 6.45 | |||||
Price-to-Median-PS-Value | 0.29 | |||||
Price-to-Graham-Number | 5.67 | |||||
Price-to-Net-Current-Asset-Value | 37.85 | |||||
Earnings Yield (Greenblatt) % | 1.26 | |||||
FCF Yield % | -4.14 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Sarepta Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 1,640.348 | ||
EPS (TTM) ($) | 1.54 | ||
Beta | 0.38 | ||
Volatility % | 42.54 | ||
14-Day RSI | 47.67 | ||
14-Day ATR ($) | 3.334231 | ||
20-Day SMA ($) | 124.21655 | ||
12-1 Month Momentum % | 36.52 | ||
52-Week Range ($) | 88.01 - 175.1 | ||
Shares Outstanding (Mil) | 95.52 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Sarepta Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Sarepta Therapeutics Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Sarepta Therapeutics Inc Frequently Asked Questions
What is Sarepta Therapeutics Inc(LTS:0L35)'s stock price today?
When is next earnings date of Sarepta Therapeutics Inc(LTS:0L35)?
Does Sarepta Therapeutics Inc(LTS:0L35) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |